Raloxifene: recent information on skeletal and non-skeletal effects.
Raloxifene, a selective estrogen receptor modulator, is currently used for both prevention and treatment of postmenopausal osteoporosis. Recent data from the MORE (Multiple Outcomes of Raloxifene Evaluation) trial have evaluated health-related quality of life, 1-year clinical vertebral fracture reduction, and the correlation of bone mineral density and biochemical markers of bone turnover with vertebral fracture reduction. In addition, new information on the effects of raloxifene in breast cancer prevention, cardiovascular disease in high-risk women, and uterine disorders is reviewed.
University of Arizona School of Medicine, Tucson, Arizona, USA.
Oscar
O
Gluck
Michael
M
Maricic
D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D001943:Breast Neoplasms / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D011788:Quality of Life; D020849:Raloxifene Hydrochloride / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D014599:Uterus / Q000187:drug effects
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride